Latest and Past News
-
The Serbia-Manitoba Chapter twinning partnership receives the WFH 2022 Twins of the Year award!
It was with great pride that the CHS learned that the World Federation of Hemophilia (WFH) had granted the 2022 Hemophilia Organization Twins of the...
-
In Memoriam – Dr. Ronald E. George
The CHS is deeply saddened to learn of the passing of Dr. Ronald George. We would like to offer our sincere condolences to his wife...
-
2023 recipients of the James Kreppner Memorial Scholarship and Bursary Program
CLICK HERE to meet the 2023 James Kreppner Scholarship and Bursary recipients.
-
Health Canada approves Alhemo (concizumab) for FIX inhibitors
Montreal – May 23, 2023 – The Canadian Hemophilia Society has learned that Health Canada recently approved Alhemo (concizumab) for the treatment of people, ages...
-
2022 CHS Annual Report
Please CLICK HERE to access the 2022 CHS Annual Report. Should you want to consult the complete Financial Statements, you can do so by clicking HERE.
-
Justice Krever is no longer with us … but his legacy is very much alive
The Commission of Inquiry on the Blood System in Canada was a public investigation of the Canadian blood system, which had been contaminated with HIV...
-
Canadian standards of care for bleeding disorders: Are they met?
Following the development of the Canadian Integrated and Comprehensive Care Standards for Inherited Bleeding Disorders (Second Edition) in 2020, the Canadian Inherited Bleeding Disorder Standards...
-
Update on coagulation products – current and in the pipeline
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE....
-
Running a marathon in record time with severe hemophilia A
by James Bayford – Kelowna, British Columbia “Why?” Is a question I asked myself as I laced up my running shoes before a scheduled 20...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Results of CHS survey on gene therapy
This past summer, the Canadian Hemophilia Society (CHS) conducted an on-line survey on attitudes to and knowledge about gene therapy. The results were presented and...
-
Héma-Québec tender selects an extended half-life FVIII
Héma-Québec announced on November 30, following its Request for Proposals for recombinant factor VIII concentrates, that it had selected Esperoct. Esperoct is approved by Health...
-
Hemophilia A gene therapy approved in Europe but possibly delayed in the U.S.
Last August, the European Medicines Agency (EMA) granted conditional marketing authorization to BioMarin’s Roctavian (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A...
-
Hemophilia B gene therapy approved by U.S. FDA
Montreal – November 28, 2022 – The U.S. Food and Drug Administration (FDA) approved the first gene therapy for hemophilia B on November 22. Etranacogene...